secwatch.observer — SEC 8-K summary
======================================

Issuer:     PMV Pharmaceuticals, Inc. (PMVP)
CIK:        0001699382
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061552
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PMV Pharma reports Q3 loss, PC14586 Phase 1 data shows 38% ORR at RP2D
----------------------------------------------------------------------

- Net loss 9mo $53.2M vs $54.0M YoY; cash $238.1M as of Sep 30, 2023.
- PC14586 PYNNACLE: 38% ORR at 2000 mg RP2D (6/16 evaluable, TP53 Y220C/KRAS wild-type).
- Median duration of response 7 months across ovarian, breast, prostate, SCLC, endometrial cancers.
- Registrational Phase 2 trial to start Q1 2024; RP2D aligned with FDA in Q3 2023 meeting.
- Raised $35.1M net via ATM facility during 9mo; R&D expenses increased to $42.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699382/000095017023061552/0000950170-23-061552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699382/000095017023061552/pmvp-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer